Drug Profile
Becaplermin biosimilar - USV
Alternative Names: PDGF-BB - USV; Platelet-derived growth factor B-chain homodimer - USVLatest Information Update: 23 Aug 2023
Price :
$50
*
At a glance
- Originator USV
- Class Blood proteins; Cicatrizants; Growth factors; Recombinant proteins
- Mechanism of Action Platelet-derived growth factor receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Diabetic foot ulcer
Most Recent Events
- 23 Aug 2023 Becaplermin biosimilar is still in preclinical trials for Diabetic foot ulcer in India (USV pipeline, August 2023)
- 28 Jun 2019 No recent reports of development identified for preclinical development in Diabetic-foot-ulcer in India (Topical, Gel)
- 22 May 2015 USV files a patent for becaplermin gel formulation in India (USV product pipeline, May 2015)